The experimental drug is an ultrasensitive version of CAR-T therapies, which have already revolutionized the treatment of leukemias and lymphomas ...

Sen. Bill Cassidy (R-Louisiana), who leads the Senate’s health panel, commits to holding a hearing to discuss the rising costs of medicine as Sen. Bernie Sanders (I-Vermont) makes a push for a ...

In an Aegis opinion piece, Sen. Mary-Dulany James highlights funding initiatives and bills she’s supporting this legislative session.

Kollar-Kotelly said in her Thursday decision that the agency violated IRS Code 6103, one of the strictest confidentiality laws in federal statute, “approximately 42,695 times by disclosing last known ...

This press release is not intended for UK media HERNEXEOS (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial1 Acceler ...

Recently published chondrosarcoma Market Insights report includes a comprehensive understanding of current treatment practices, chondrosarcoma emerging drugs, market share of individual therapies, and ...

Building an AI infrastructure for biotech. Bacteria that munch on cancer. How to best make a cold brew. All that and more in ...

Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar ...

Neuromod Devices, an Irish medical technology business specialising in tinnitus treatment, has announced plans to commercialise the Lenire tinnitus treatment device in Canada and Australia in 2026.

DESMODA is the first and only FDA-approved desmopressin oral solutionCommercial launch expected on March 9thDESMODA eliminates tablet splitting and crushing, enabling precise, individualized dosing fo ...

Gemma Biotherapeutics ("GEMMABio"), a clinical?stage global genetic medicines company, announced today that the first patient has been dosed in the Phase 1/2 CHARISMA clinical trial of GB221, an ...

ADMA Biologics ADMA reported fourth-quarter 2025 adjusted earnings per share (EPS) of 21 cents, (excluding stock-based ...